Deutsche Bank Reiterates Bullish Stance on Regeneron (REGN)
Tweet Send to a FriendGet Alerts REGN Hot Sheet
Price: $263.64 -1.25%
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade REGN Now!
Deutsche Bank reiterated their Buy rating and $165 price target on Regeneron Pharma (NASDAQ: REGN) following results this morning.
The firm said Eylea should continue to growth and competition is still far off.
"We believe current selling is overdone as anti-PDGF will unlikely be a competition to Eylea unless the competitors 1) Collaborate with Opthotech AND 2) Come up with a right co formulated dose which can be given as a single injection in the eye in combination with Lucentis. We continue to see Eylea uptake and believe Eylea will grow more once permanent J code gets on-line in Jan-2013... We note that even in the event of successful co-formulation, the competition will have to go through large clinical studies and regulatory approval process. We do not see any competition coming in play before 2017 timeframe."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $121.44 yesterday, with a 52 week range of $42.83-$145.04.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said Eylea should continue to growth and competition is still far off.
"We believe current selling is overdone as anti-PDGF will unlikely be a competition to Eylea unless the competitors 1) Collaborate with Opthotech AND 2) Come up with a right co formulated dose which can be given as a single injection in the eye in combination with Lucentis. We continue to see Eylea uptake and believe Eylea will grow more once permanent J code gets on-line in Jan-2013... We note that even in the event of successful co-formulation, the competition will have to go through large clinical studies and regulatory approval process. We do not see any competition coming in play before 2017 timeframe."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $121.44 yesterday, with a 52 week range of $42.83-$145.04.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Merck's (MRK) Suvorexant Faces Challenges at FDA
- Goldman Sachs Downgrades Thoratec (THOR) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
